TY - JOUR
T1 - CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells
AU - Miyagi, K.
AU - Kawakami, K.
AU - Kinjo, Y.
AU - Uezu, K.
AU - Kinjo, T.
AU - Nakamura, K.
AU - Saito, A.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/5
Y1 - 2005/5
N2 - In the present study, we elucidated the effect of synthetic CpG-containing oligodeoxynucleotides (ODN) on pulmonary and disseminated infection caused by Cryptococcus neoformans. CDF-1 mice were inoculated intratracheally with a highly virulent strain of this pathogen, which resulted in massive bacterial growth in the lung, dissemination to the brain and death. Administration of CpG-ODN promoted the clearance of C. neoformans in the lungs, decreased their dissemination to brain and prolonged the survival of infected mice. These effects correlated well with the enhanced production of interleukin (IL)-12 and interferon (IFN)-γ and attenuated secretion of IL-4 in bronchoalveolar lavage fluids (BALF) and promoted development of Th1 cells, as indicated by the increased production of IFN-γ by paratracheal lymph node cells upon restimulation with cryptococcal antigens. The IFN-γ synthesis in BALF was inhibited by depletion of CD8+ and CD4+ T cells on days 7 and 14 after infection, respectively, but not by depletion of NK and γδ T cells. Consistent with these data, intracellular expression of IFN-γ was detected predominantly in CD8+ and CD4+ T cells in the lung on days 7 and 14, respectively. The protective effect of CpG-ODN, as shown by the prolonged survival, was completely and partially inhibited by depletion of CD4+ or CD8+ T cells, respectively, but not by depletion of other cells. Finally, TNF-α was markedly induced by CpG-ODN, and the protective effect of this agent was strongly inhibited by neutralizing anti-TNF-α MoAb. Our results indicate that CpG-ODN alters the Th1-Th2 cytokine balance and promotes host resistance against infection with C. neoformans.
AB - In the present study, we elucidated the effect of synthetic CpG-containing oligodeoxynucleotides (ODN) on pulmonary and disseminated infection caused by Cryptococcus neoformans. CDF-1 mice were inoculated intratracheally with a highly virulent strain of this pathogen, which resulted in massive bacterial growth in the lung, dissemination to the brain and death. Administration of CpG-ODN promoted the clearance of C. neoformans in the lungs, decreased their dissemination to brain and prolonged the survival of infected mice. These effects correlated well with the enhanced production of interleukin (IL)-12 and interferon (IFN)-γ and attenuated secretion of IL-4 in bronchoalveolar lavage fluids (BALF) and promoted development of Th1 cells, as indicated by the increased production of IFN-γ by paratracheal lymph node cells upon restimulation with cryptococcal antigens. The IFN-γ synthesis in BALF was inhibited by depletion of CD8+ and CD4+ T cells on days 7 and 14 after infection, respectively, but not by depletion of NK and γδ T cells. Consistent with these data, intracellular expression of IFN-γ was detected predominantly in CD8+ and CD4+ T cells in the lung on days 7 and 14, respectively. The protective effect of CpG-ODN, as shown by the prolonged survival, was completely and partially inhibited by depletion of CD4+ or CD8+ T cells, respectively, but not by depletion of other cells. Finally, TNF-α was markedly induced by CpG-ODN, and the protective effect of this agent was strongly inhibited by neutralizing anti-TNF-α MoAb. Our results indicate that CpG-ODN alters the Th1-Th2 cytokine balance and promotes host resistance against infection with C. neoformans.
KW - CpG-DNA
KW - Cryptococcus neoformans
KW - Lung
KW - Th1-Th2 balance
UR - http://www.scopus.com/inward/record.url?scp=17644384554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17644384554&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2249.2005.02772.x
DO - 10.1111/j.1365-2249.2005.02772.x
M3 - Article
C2 - 15807845
AN - SCOPUS:17644384554
VL - 140
SP - 220
EP - 229
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
SN - 0009-9104
IS - 2
ER -